NeurAxis (NASDAQ:NRXS) Trading Up 5.5% - Here's What Happened

Key Points

• Shares jumped 5.5% on Friday to an intraday high of $8.40 and last traded at $7.86, with volume about 530,476 shares—roughly a 245% increase versus the average daily volume.
• Craig Hallum raised its price target from $8.00 to $13.00 and issued a "buy" rating, leaving NeurAxis with a consensus rating of Buy and a consensus price target of $13.00.
• NeurAxis is a clinical-stage CNS-focused biotech with a market cap of about $87.9 million, a negative P/E (-4.27), and technicals showing a 50-day SMA of $6.62 versus a 200-day SMA of $4.61, indicating recent upward momentum.

NeurAxis, Inc. (NASDAQ:NRXS - Get Free Report)'s stock price was up 5.5% during trading on Friday . The company traded as high as $8.40 and last traded at $7.86. Approximately 530,476 shares changed hands during trading, an increase of 245% from the average daily volume of 153,901 shares. The stock had previously closed at $7.45.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum lifted their price target on shares of NeurAxis from $8.00 to $13.00 and gave the company a "buy" rating in a research note on Friday, March 20th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, NeurAxis presently has a consensus rating of "Buy" and a consensus price target of $13.00.

NeurAxis Stock Performance

The firm's 50 day simple moving average is $6.62 and its 200-day simple moving average is $4.61. The company has a market cap of $87.94 million, a price-to-earnings ratio of -4.27 and a beta of 1.89.

Institutional Investors Weigh In On NeurAxis

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRXS. Money Concepts Capital Corp acquired a new stake in NeurAxis during the 3rd quarter worth $103,000. Citadel Advisors LLC boosted its stake in NeurAxis by 39.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company's stock worth $110,000 after purchasing an additional 10,103 shares during the last quarter. Manatuck Hill Partners LLC acquired a new stake in NeurAxis during the 2nd quarter worth $122,000. State Street Corp acquired a new stake in NeurAxis during the 4th quarter worth $139,000. Finally, Geode Capital Management LLC boosted its holdings in shares of NeurAxis by 48.8% during the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company's stock worth $343,000 after purchasing an additional 24,817 shares during the last quarter. Institutional investors and hedge funds own 11.77% of the company's stock.

About NeurAxis

NeurAxis NASDAQ: NRXS is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.